Want to see VRDN full AI Analyst Report?
VRDN Stock Chart & Stats
$14.80
-$0.50(-1.51%)
At close: 4:00 PM EST
$14.80
-$0.50(-1.51%)
Day’s Range― - ―
52-Week Range$13.18 - $34.29
Previous CloseN/A
Volume140.31K
Average Volume (3M)2.25M
Market Cap
$2.04B
Enterprise Value$1.38B
Total Cash (Recent Filing)$762.18M
Total Debt (Recent Filing)$51.17M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Aug 12, 2026EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.48
Shares Outstanding110,427,680
10 Day Avg. Volume1,727,386
30 Day Avg. Volume2,253,088
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)3.65
Price to Sales (P/S)37.25
P/FCF Ratio-9.53
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue19.44
Enterprise Value/Gross Profit19.56
Enterprise Value/Ebitda-3.95
Forecast
1Y Price Target
$35.25Price Target Upside138.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.81
Revenue Forecast (FY)$27.66M
Bulls Say, Bears Say
Bulls Say
Pivotal Phase 3 SuccessTwo positive pivotal Phase 3 readouts (REVEAL-1 and REVEAL-2) and a targeted BLA in early 2027 materially de-risk regulatory approval. Durable regulatory progress supports commercialization planning, reimbursement discussions, and competitive positioning in thyroid eye disease beyond near-term market noise.
Commercial Manufacturing AgreementA five-year commercial manufacturing pact with WuXi secures scalable drug substance and product supply with flexible, non-exclusive terms and volume pricing. This reduces execution risk for launch, preserves sourcing options, and supports sustainable supply chain capacity as the company moves from clinical to commercial operations.
Improved Liquidity And Lower LeverageA combined equity and convertible offering (~$359M) plus actions to remove the Hercules loan strengthen liquidity and reduce reliance on higher-cost debt. Paired with a low debt-to-equity (~0.08), these moves extend runway into potential commercial launch and increase financial flexibility for market expansion and R&D investments.
Bears Say
High Cash BurnSustained negative operating and free cash flow of roughly -$303M TTM indicates large ongoing funding needs. Over the medium term this pressure requires continued access to capital markets or partnerships, raising execution risk and potentially constraining investments or commercialization pacing until positive cash generation is achieved.
No Marketed Products / Financing RelianceAs a clinical-stage biotech with no product revenue, Viridian remains financing-dependent until approvals and commercial launches. This structural reliance on capital markets or collaborations makes the business binary on regulatory success and exposes long-term strategy to investor sentiment and funding availability.
Large Operating Losses And Weak MarginsVery large net losses relative to modest revenue reflect a high expense base and deeply negative margins. Persistent losses erode returns on equity and require continued funding, which can dilute shareholders, limit reinvestment options, and delay attainment of sustainable profitability even after product approvals.
Viridian Therapeutics News
VRDN FAQ
What was Viridian Therapeutics, Inc.’s price range in the past 12 months?
Viridian Therapeutics, Inc. lowest stock price was $13.18 and its highest was $34.29 in the past 12 months.
What is Viridian Therapeutics, Inc.’s market cap?
Viridian Therapeutics, Inc.’s market cap is $2.04B.
When is Viridian Therapeutics, Inc.’s upcoming earnings report date?
Viridian Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 41 days.
How were Viridian Therapeutics, Inc.’s earnings last quarter?
Viridian Therapeutics, Inc. released its earnings results on May 05, 2026. The company reported -$0.9 earnings per share for the quarter, beating the consensus estimate of -$1.081 by $0.181.
Is Viridian Therapeutics, Inc. overvalued?
According to Wall Street analysts Viridian Therapeutics, Inc.’s price is currently Undervalued.
Does Viridian Therapeutics, Inc. pay dividends?
Viridian Therapeutics, Inc. does not currently pay dividends.
What is Viridian Therapeutics, Inc.’s EPS estimate?
Viridian Therapeutics, Inc.’s EPS estimate is -1.02.
How many shares outstanding does Viridian Therapeutics, Inc. have?
Viridian Therapeutics, Inc. has 110,427,680 shares outstanding.
What happened to Viridian Therapeutics, Inc.’s price movement after its last earnings report?
Viridian Therapeutics, Inc. reported an EPS of -$0.9 in its last earnings report, beating expectations of -$1.081. Following the earnings report the stock price went up 33.357%.
Which hedge fund is a major shareholder of Viridian Therapeutics, Inc.?
Currently, no hedge funds are holding shares in VRDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viridian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.25 (138.18% Upside)
$35.25 (138.18% Upside)
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 6.9%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
31.40%
12-Months-Change
Fundamentals
Return on Equity
-60.70%
Trailing 12-Months
Asset Growth
19.37%
Trailing 12-Months
Company Description
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
VRDN Stock 12 Month Forecast
Average Price Target
$35.25
▲(138.18% Upside)
Technical Analysis
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
4.66% Insiders
26.25% Mutual Funds
41.13% Other Institutional Investors
12.72% Public Companies and
Individual Investors